Sonoma Pharmaceuticals is a global healthcare provider for developing and producing stabilized hypochlorous acid products for a range of applications, including wound care, animal health care, eye care, oral care and dermatological conditions. Co.'s products include: Celacyn® Scar Management Gel, which provides scar management by protecting and moisturizing wound and scar sites; Microcyn® Wound Care Management, which provides improved healing properties; Acuicyn Eyelid and Eyelash Hygiene, which provides eyelid and eyelash hygiene; and Microdacyn60® Oral Care, which supports the treatment of mouth and throat infections and the debridement and moistening of mouth lesions and thrush. The SNOA stock yearly return is shown above.
The yearly return on the SNOA stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2020 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SNOA annual return calculation with any dividends reinvested as applicable (on ex-dates).
|